Why is "Adagrasib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-12 21:13:11
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of G12C mutated KRAS GTPase. It is taken by mouth. It is being developed by Mirati Therapeutics.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Adagrasib shows meaningful benefits in older patients with mutated NSCLC - ESMO Daily Reporter
-
Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC - Medscape
-
Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer - Nature
-
Adagrasib (Krazati) Patient Guide 2025: Targeted Therapy for Lung and Colorectal Cancer - Oncodaily
-
-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet
-
Adagrasib vs Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C–Mutated NSCLC - The ASCO Post
-
Rx Road Map: Adagrasib With Cetuximab for KRAS G12C-Mutated mCRC - Oncology Nursing News
-
Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC - CancerNetwork
-
Adagrasib + Pembrolizumab Shows Promising Efficacy, Safety in Untreated Advanced KRAS - ASCO Daily News
-
Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib - PNAS
-
Adagrasib Outperforms Docetaxel in KRAS -Mutant NSCLC - Cancer Therapy Advisor
-
Adagrasib Demonstrates Favorable PFS in Advanced KRAS G12C-Mutated NSCLC - Pharmacy Times
-
Adagrasib Plus Pembrolizumab Shows Best Efficacy in PD-L1–High NSCLC - Targeted Oncology
-
Adagrasib Plus Pembro Beneficial in KRAS G12C-Mutated NSCLC: New Phase 2 Data - Oncology News Central
-
Adagrasib (Krazati) Updates 2025: Uses in Cancer, Side Effects, Dosages, Expectations, and More - Oncodaily
-
Adagrasib for KRASG12C mutated advanced non-small-cell lung cancer - The Lancet
-
Adagrasib/Pembrolizumab Yields Improved Survival in KRAS G12C-Mutated NSCLC - CancerNetwork
-
Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC - Targeted Oncology
-
Beyond Monotherapy: Evolving Combination Therapies for KRASG12C–Mutant Colorectal Cancer - ASCO Daily News
-
Adagrasib for KRASG12C mutated advanced non-small-cell lung cancer - The Lancet
-
First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC - Targeted Oncology
-
KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer - MedPage Today
-
KRYSTAL-7 Phase II Trial First-Line Adagrasib Plus Pembrolizumab Delivers Durable Responses Across PD-L1 Levels in KRASG12C-Mutated NSCLC - Oncodaily
-
Sotorasib More Cost-Effective in KRAS G12C NSCLC - AJMC
-
KRAS Inhibitors Show Efficacy in Randomized NSCLC Trials - Targeted Oncology
-
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation - NEJM
-
KRYSTAL-12 Shows PFS Benefit With Adagrasib Over Docetaxel in Previously-Treated Advanced KRAS - ASCO Daily News
-
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer - The ASCO Post
-
Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer - ACS Publications
-
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases - UT MD Anderson
-
Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC - Targeted Oncology
-
Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC - OncLive
-
Dr Herzberg on the Distinctions Between Sotorasib and Adagrasib for KRAS G12C+ NSCLC - OncLive
-
Adagrasib Improves Survival, Responses in KRAS G12C+ Advanced NSCLC - OncLive
-
Adagrasib Combo Continues to Show Efficacy in KRAS G12C–Mutated NSCLC and PD-L1 ≥50% - OncLive
-
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC - OncLive
-
Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC - OncLive
-
Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC - AJMC
-
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C - NEJM
-
FDA Grants Accelerated Approval to Adagrasib With Cetuximab for KRAS G12C-Mutated Colorectal Cancer - Oncology News Central
-
Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC - OncLive
-
KRAS Mutant Colorectal Cancer Active and Recruiting Trials You Need to Know in 2025 - Oncodaily
-
Adagrasib Plus Cetuximab Potential Standard for KRAS G12C-mutated CRC - Oncology News Central
-
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - PR Newswire
-
FDA Approves Adagrasib With Cetuximab in KRAS G12C-Mutated CRC - Targeted Oncology
-
Adagrasib Significantly Improves PFS Vs Chemo in KRAS G12C-Mutated NSCLC - CancerNetwork
-
Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC - OncLive
-
Adagrasib Shows Promise in Additional Pretreated Solid Tumors with KRAS G12C Mutation - Oncology News Central
-
Adagrasib Demonstrates Activity in Advanced KRAS G12C –Mutant Tumors - ASCO Daily News
-
FDA Approves Adagrasib Plus Cetuximab for KRAS G12C–Mutant CRC - OncLive
-
KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors - The ASCO Post
-
Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC - OncLive
-
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer - PR Newswire
-
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - PR Newswire
-
D3 Bio raises $108M series B to move KRAS G12C into phase III - BioWorld News
-
Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC - OncLive
-
Long-Term Data Show Adagrasib Is Safe, Effective in KRAS G12C-Mutated NSCLC - Oncology News Central
-
KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials - The ASCO Post
-
Acquired Resistance to KRASG12C Inhibition in Cancer - NEJM
-
Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC - OncLive
-
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Ca - PR Newswire
-
Impact of Sotorasib and Adagrasib in KRAS G12C–Mutated NSCLC - CancerNetwork
-
Adagrasib Demonstrates Intracranial Activity in KRAS G12C+ NSCLC - CancerNetwork
-
Adagrasib Demonstrates Superiority in KRAS G12C NSCLC - Targeted Oncology
-
FDA Approves Adagrasib for Locally Advanced or Metastatic KRAS G12C+ NSCLC - OncLive
-
FDA Approves Adagrasib for Use in Previously Treated CRC - AJMC
-
CHMP Advises Against Adagrasib Approval for KRAS G12C–Mutant Advanced NSCLC - OncLive
-
Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC - OncLive
-
Rx Road Map: Adagrasib (Krazati) - Oncology Nursing News
-
FDA Approves Adagrasib for KRAS G12C–Mutated CRC - Medscape
-
KRYSTAL-12 Study of Adagrasib Meets Primary End Point in KRAS G12C NSCLC - Targeted Oncology
-
Adagrasib With Cetuximab Moves Into Phase 3 for KRAS G12C–Mutated CRC - OncLive
-
Adagrasib Shows Promise in KRAS G12C-Mutated Non–Small Cell Lung Cancer With Active, Untreated Brain Metastases - ASCO Daily News
-
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) - PR Newswire
-
Second KRAS Inhibitor Represents Another Standard in Patients with Non-Small-Cell Lung Cancer and KRASG12C Mutation - Cleveland Clinic
-
FDA Grants Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC - OncLive
-
FDA Approves Adagrasib (Krazati) in KRAS G12C-Mutated NSCLC - Oncology News Central
-
Oncology Overview: Adagrasib (MRTX849) for Non-Small Cell Lung Cancer - Pharmacy Times
-
Sotorasib, Adagrasib Therapy Is “Reasonable” Strategy in KRAS G12C+ NSCLC - CancerNetwork
-
Adagrasib Penetrates CNS in Early Data of KRAS G12C+ NSCLC - Targeted Oncology
-
FDA Grants Accelerated Approval to Adagrasib With Cetuximab for KRAS G12C–Mutated Colorectal Cancer - The ASCO Post
-
FDA Approves Adagrasib for KRAS G12C-Mutant Locally Advanced/Metastatic NSCLC - Targeted Oncology
-
Jacobio Pharma and AstraZeneca Strike $2 B Deal for Pan‑KRAS Inhibitor - Oncodaily
-
Encouraging Results for Adagrasib Observed in Patients With KRAS G12C-Mutated GI Malignancies - ASCO Daily News
-
European Commission Approves Adagrasib in KRAS G12C-Mutated NSCLC - CancerNetwork
-
Drugging an “Undruggable” Protein - American Association for Cancer Research (AACR)
-
KRAS Inhibitor Regimen Approved for Colorectal Cancer - American Association for Cancer Research (AACR)
-
Discussing the Management of KRAS Inhibitors in NSCLC - Targeted Oncology
-
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC) - PR Newswire
-
Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab - 2 Minute Medicine
-
Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC - The ASCO Post
-
Krazati (adagrasib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC), USA - Clinical Trials Arena
-
Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation - The ASCO Post
-
Positive preliminary results for combination therapy with adagrasib in KRAS G12C-mutated NSCLC - ESMO Daily Reporter
-
FDA Approves ctDx FIRST as Liquid Biopsy Companion Diagnostic Test for Adagrasib in Advanced NSCLC - OncLive
-
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer - PR Newswire
-
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure - PR Newswire
-
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation - 2 Minute Medicine
-
FDA Approves Adagrasib for KRAS G12C-Mutated Metastatic Colorectal Cancer - Oncology Nursing News
-
Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases - OncLive
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.